Ultragenyx Pharmaceutical Inc. Uncategorized Contracts & Agreements
28 Contracts & Agreements
- Amendment dated September 6, 2023 to the Offer Letter between Howard Horn and Ultragenyx Pharmaceutical Inc. dated June 22, 2023 (Filed With SEC on September 8, 2023)
- Offer Letter between Howard Horn and Ultragenyx Pharmaceutical Inc. dated June 22, 2023 (Filed With SEC on July 12, 2023)
- Amendment, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and John R. Pinion II (Filed With SEC on November 3, 2022)
- Amendment No. 3, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Erik Harris (Filed With SEC on November 3, 2022)
- Amendment, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Dennis Huang (Filed With SEC on November 3, 2022)
- Amendment, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Karah Parschauer (Filed With SEC on November 3, 2022)
- Amendment No. 2, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Thomas Kassberg (Filed With SEC on November 3, 2022)
- Amendment No. 2, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Mardi C. Dier (Filed With SEC on November 3, 2022)
- Amendment, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Camille Bedrosian, M.D (Filed With SEC on November 3, 2022)
- Open Market Sale Agreement, dated May 7, 2021, by and between Ultragenyx Pharmaceutical Inc. and Jefferies LLC (Filed With SEC on May 7, 2021)
- Amendment dated October 9, 2020 to the Offer Letter between Mardi C. Dier and Ultragenyx Pharmaceutical Inc. dated August 28, 2020 (Filed With SEC on October 13, 2020)
- Offer Letter between Mardi C. Dier and Ultragenyx Pharmaceutical Inc. dated August 28, 2020 (Filed With SEC on September 2, 2020)
- Addendum #2, dated June 19, 2019, to Offer Letter dated May 16, 2017 between Ultragenyx Pharmaceutical Inc. and Erik Harris (Filed With SEC on August 2, 2019)
- Addendum #1, dated August 8, 2017, to Offer Letter dated May 16, 2017 between Ultragenyx Pharmaceutical Inc. and Erik Harris (Filed With SEC on August 2, 2019)
- Offer Letter, dated May 16, 2017, by and between Ultragenyx Pharmaceutical Inc. and Erik Harris (Filed With SEC on August 2, 2019)
- Offer Letter, dated August 2, 2018 (Filed With SEC on September 17, 2018)
- Turning good science into great medicine (Filed With SEC on February 17, 2017)
- Turning good science into great medicine (Filed With SEC on February 17, 2017)
- Turning good science into great medicine (Filed With SEC on February 17, 2017)
- ULTRAGENYX PHARMACEUTICAL INC. $150,000,000 SALESAGREEMENT (Filed With SEC on July 5, 2016)
- ADDENDUM TWO (Filed With SEC on February 26, 2016)
- Addendum One (Filed With SEC on February 26, 2016)
- CONFIDENTIAL TREATMENT REQUESTED [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential... (Filed With SEC on November 10, 2015)
- Ultragenyx Pharmaceutical Inc. (Filed With SEC on August 14, 2015)
- LicenseAgreement (Filed With SEC on December 23, 2013)
- ULTRAGENYX PHARMACEUTICAL INC. AMENDMENT TO THE 2011 EQUITYINCENTIVE PLAN (Filed With SEC on November 8, 2013)
- LicenseAgreement (Filed With SEC on November 8, 2013)
- State of Delaware (Filed With SEC on November 8, 2013)
